Literature DB >> 10419784

Animal models of arthritis in NOS2-deficient mice.

W B van den Berg1, F van de Loo, L A Joosten, O J Arntz.   

Abstract

OBJECTIVE: To study the role of nitric oxide (NO) in cartilage destruction in murine models of arthritis and osteoarthritis.
METHODS: Joint inflammation was induced in the knee joint by intraarticular injection of Zymosan. Osteoarthritis was induced by local injection of bacterial collagenase, causing joint instability. The effect of NO deficiency was studied by comparing the effects in normal mice and mice with genetically disrupted NOS2 (inducible NO synthase). Impact on articular cartilage was evaluated by histology and measurement of chondrocyte 35S-proteoglycan synthesis.
RESULTS: NOS2 deficiency prevented chondrocyte proteoglycan synthesis inhibition in the arthritic cartilage and restored normal responsiveness to IGF-1. Net cartilage proteoglycan depletion was markedly reduced in the absence of NOS2, although inflammation was hardly affected. Osteoarthritic joint pathology was also significantly reduced, including diminished cartilage lesions and osteophyte formation.
CONCLUSION: NO plays a major role in cartilage damage in both arthritic and osteoarthritic conditions. Copyright 1999 OsteoArthritis Research Society International.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419784     DOI: 10.1053/joca.1999.0228

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  19 in total

Review 1.  Nitric oxide synthases and osteoarthritis.

Authors:  Jose U Scher; Michael H Pillinger; Steven B Abramson
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

2.  Inducible nitric oxide synthase is expressed in synovial fluid granulocytes.

Authors:  J Cedergren; T Forslund; T Sundqvist; T Skogh
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 3.  Disease-modifying therapies for osteoarthritis : current status.

Authors:  Marc Fajardo; Paul E Di Cesare
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis.

Authors:  C M Davies; F Guilak; J B Weinberg; B Fermor
Journal:  Osteoarthritis Cartilage       Date:  2007-10-22       Impact factor: 6.576

5.  Interleukin-1 and tumor necrosis factor alpha inhibit repair of the porcine meniscus in vitro.

Authors:  A Hennerbichler; F T Moutos; D Hennerbichler; J B Weinberg; F Guilak
Journal:  Osteoarthritis Cartilage       Date:  2007-04-19       Impact factor: 6.576

Review 6.  Cell biology of osteoarthritis: the chondrocyte's response to injury.

Authors:  N Fukui; C R Purple; L J Sandell
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

Review 7.  Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis.

Authors:  S B Abramson; M Attur; A R Amin; R Clancy
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

8.  Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes.

Authors:  Nahid Akhtar; Mark Js Miller; Tariq M Haqqi
Journal:  BMC Complement Altern Med       Date:  2011-08-19       Impact factor: 3.659

9.  The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage.

Authors:  Martin H Stradner; Hannes Angerer; Thomas Ortner; Florentine C Fuerst; Daniela Setznagl; Marie-Luise Kremser; Josef Hermann; Winfried B Graninger
Journal:  BMC Musculoskelet Disord       Date:  2011-12-12       Impact factor: 2.362

10.  Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production.

Authors:  Katriina Vuolteenaho; Anna Koskinen; Meiju Kukkonen; Riina Nieminen; Unto Päivärinta; Teemu Moilanen; Eeva Moilanen
Journal:  Mediators Inflamm       Date:  2009-08-13       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.